MedTrace Logo

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

NCT05417932 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-02-18

No results posted yet for this study

Summary

This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

Conditions

  • Hepatitis B Virus Related Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Recurrent

Interventions

BIOLOGICAL

SCG101

Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.

Sponsors & Collaborators

  • SCG Cell Therapy Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • SCG Cell Therapeutics · SCG Cell Therapy Pte. Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-26
Primary Completion
2025-09-30
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States
  • Hong Kong
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417932 on ClinicalTrials.gov